Print this page
Sarcoma
-
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma.
Protocol: 112205Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma.
Protocol: 112205Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma.
Protocol: 112303Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints -
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma.
Protocol: 112303Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints -
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors.
Protocol: 112401-01APrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors.
Protocol: 112401-01APrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site